Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity.
Purity:
95.00%
CAS Number:
[1310460-85-5]
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted